Bayer HealthCare LLC has signed an agreement to acquire Teva Pharmaceutical’s U.S. animal health business for as much as $145 million, which includes a $60 million upfront payment and a total of $85 million in milestones associated with manufacturing and sales targets. The acquisition expands Bayer’s companion and food animal product lines in the U.S. Teva plans to focus its efforts on human health and its core expertise in generic and branded medicines. The transaction, which includes a manufac...